© Ulrich M Gasser 2019 Big Data & Research
– Acquisition, Analytics, and Exploitation

May 2019. Claims of doing “research”, in particular to pursue “scientific” interests are regularly invoked when it comes to be exempted from common regulations or claim privileges. This is particularly evident, if acquiring, analysing, or exploiting “Big Data”. While proven scientific pursuits rightly enjoy public privileges, blanket attributions of doing nothing else but “science”, inflationary exploit of research privileges, or dubious roles of “scientists” have been raising widespread public concerns.

Ulrich Gassner, Professor of Public Law at Universität Augsburg (DE) offers a legal perspective from current debates in German and EU regulations (including GDPR). He is also partner in DigiMed, a Big Data healthcare project by the Bavarian Government designed to explore critical issues in political control of borderless technological transformation.

If you like to read this article, you can purchase it now

Please notice, If you order by email from an organisation - for-profit or nonprofit alike - you must buy an organisation sharing license and cannot buy an individual license. However the organisation sharing license entitles you to share the article with up to four other individuals - provided you adhere to the Terms and Conditions which you agree with when purchasing articles of B2Bioworld.

Read Now - Please select your license (Prices incl. 7% VAT)
8 pages free of advertisement

Article free of advertisement

Full Company License enquire here

Back to section

Other Articles Recommended

B2Biioworld offers you background information

Regulatory Challenges of Big Data Operations – Algorithms, Healthcare, or Autonomous Driving
Herbert Zech, Professor of Life Sciences and Intellectual Property Laws at Universität Basel on key juridical concepts of the current debate about big data and artificial intelligence applications beyond privacy laws

Crowd Sourcing Actionable Health Diagnoses
Dekel Gelbman, CEO of the FDNA Group on applying mobile face resp. pattern recognition for discovering individuals with genetic pathologies and rare diseases

AI-enabled Digital Pathology: Correlate anything with everything?
Ralf Huss, Chief Medical Officer Definiens AG. Interview and Comment: Automated and Whole Slide Imaging for Pathology 2018

Mastering Personal Health: Roche prepares itself for user innovation
Ursula B. Redeker, CEO of Roche Germany, CEO of Roche Germany about managing “big health data”, insourcing missing expertise, and linking up to the ecosystem

Philanthropy re-visited: Merck’s focus on Africa
Stefan Oschmann, CEO and Chairman of the Executive Board Merck KGaA in an unplugged enquiry by B2Bioworld

Steering Health Data For or By? The User as Stakeholder, Expert, Citizen, Consumer, and Patient
Thomas Szucs, Chairman of Swiss Helsana Group on putting “big data” to work in insurance and healthcare

Learning Fitted to Technologies, or Technologies for Learning
Hanne Leth Andersen, Professor of University Pedagogy at Danish Roskilde University invites readers of B2Bioworld to a light-hearted and thought-provoking tour de ronde